mynth
← DATABASE
08/2014100%

Cytosport acquired by Hormel Foods

UNITED STATES Food Processing / Food Products EV $300–700M

Context

Hormel Foods closed its acquisition of CytoSport Holdings, the maker of Muscle Milk products, on August 12, 2014. Hormel Foods bought the Benicia, California-based sports nutrition business from the Pickett family, which founded it in 1998, and from TSG Consumer Partners, giving both sellers a full exit. The purchase price was $300–700M, against total 2014 annual sales expected to be $250–500M. Hormel Foods said it expected the acquisition to add about 5 cents per share in fiscal 2015, with a neutral effect on fiscal 2014 earnings including transaction costs. The deal was announced as closed, so no closing conditions remain outstanding. CytoSport's brands, led by Muscle Milk, the top brand in the ready-to-drink protein beverage category, fit Hormel Foods' focus on protein and broaden its portfolio. The acquisition is intended as a growth catalyst for the Specialty Foods segment and extends the company's range of portable, protein-rich foods.

-> Deep-dive in AgriFood market trends

Target

Founded in 2014 through Hormel Foods' acquisition of CytoSport Holdings, Inc., the business manufactures sports nutrition products under the Muscle Milk brand. Its portfolio spans ready-to-drink beverages, protein-based powders, sports nutrition bars and energy chews. In 2017, CytoSport introduced Evolve, a plant-based and vegan protein line featuring shelf-stable shakes, powders and bars made with pea protein. The company targets athletes, fitness enthusiasts and consumers seeking convenient protein options across retail channels. Its dual-brand approach pairs a mainstream sports nutrition label with a plant-based alternative, addressing a broadening range of dietary preferences within the category.

Ent. Value

$300–700M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (USD)

Year
Rev
EBITDA
EBIT
2014
$250–500M
$25–50M
[members only]
2013
$250–500M
$25–50M
[members only]

Other operations with Cytosport

Other operations with Cytosport
DateAcquirerTargetCountrySector
04/2019PEPSICOCYTOSPORTUNITED STATESFood Products

Other operations with Hormel Foods

Other operations with Hormel Foods
DateAcquirerTargetCountrySector
09/2026HORMEL FOODSBRAKEBUSHUNITED STATESMeat & Cured Meat
05/2015HORMEL FOODSAPPLEGATEUNITED STATESMeat & Cured Meat

Similar deals in Food Processing

Similar deals in Food Processing
DateAcquirerTargetCountrySector
12/2014OLAM INTERNATIONALMCCLESKEY MILLSUNITED STATESIngredients
11/2014YILDIZ HOLDINGUNITED BISCUITS (UB)UNITED KINGDOMFood Products
07/2014EGERIAGOODLIFE FOODSNETHERLANDSFood Products
06/2014PAI PARTNERSLABEYRIE FINE FOODSFRANCEFood Products
04/201421 INVESTFORNO D’ASOLOITALYBakery / Pastry
04/2014SYMRISEDIANA GROUPFRANCEIngredients
03/2014CHARTERHOUSENUOVA CASTELLIITALYDairy
02/2014RIVERSIDECASA OPTIMAITALYIngredients
02/2014SOLINA GROUPSFK FOODDENMARKIngredients
12/2013DANTE BIGI S.R.L.GRUPPO ALIVALITALYDairy

REFERENCES

Valuation range: EV $300–700M

Revenue range: $250–500M

EBITDA range: $25–50M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Cytosport by Hormel Foods are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers Hormel Foods’s acquisition of 100% of Cytosport, an American company specialised in Food Products, in 2014. Ownership has since evolved, leading to a subsequent transaction with Pepsico in April 2019 (see the dedicated deal page for details).

How was the acquisition of Cytosport by Hormel Foods valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $300–700M band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Cytosport’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Cytosport generated annual revenue estimated in the $250–500M range and EBITDA in the $25–50M bracket (FY 2014). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.